Compare Stocks

Enter up to five stock symbols separated by a comma or space (ex. BAC,WFC,JPM,LON:BARC).
Date Range: 

 Eli Lilly and
SymbolNYSE:LLY
Price Information
Current Price$187.05
52 Week RangeBuy
MarketRank™
Overall Score2.1
Analysis Score2.4
Community Score2.8
Dividend Score2.5
Ownership Score1.7
Earnings & Valuation Score1.3
Analyst Ratings
Consensus RecommendationBuy
Consensus Price Target$199.14
% Upside from Price Target6.47% upside
Trade Information
Market Cap$179.38 billion
Beta0.37
Average Volume4,135,091
Sales & Book Value
Annual Revenue$22.32 billion
Price / Sales8.04
Cashflow$7.14 per share
Price / Cash26.19
Book Value$2.81 per share
Price / Book66.57
Profitability
Net Income$8.32 billion
EPS$6.04
Trailing P/E Ratio30.56
Forward P/E Ratio23.44
P/E Growth1.57
Net Margins24.01%
Return on Equity (ROE)166.45%
Return on Assets (ROA)15.18%
Dividend
Annual Payout$3.40
Dividend Yield1.82%
Three-Year Dividend Growth42.31%
Payout Ratio56.29%
Years of Consecutive Dividend Growth1 Years
Debt
Debt-to-Equity Ratio3.27%
Current Ratio1.36%
Quick Ratio1.06%
Ownership Information
Institutional Ownership Percentage75.59%
Insider Ownership Percentage0.09%
Miscellaneous
Employees35,000
Shares Outstanding958.99 million
Next Earnings Date4/27/2021 (Confirmed)
OptionableOptionable
SourceHeadline
Lilly to seek industry-first FDA nod in autoimmune hair loss after Olumiants second trial winLilly to seek industry-first FDA nod in autoimmune hair loss after Olumiant's second trial win
fiercepharma.com - April 22 at 1:51 PM
Eli Lilly retakes innovation crown, while Bristol Myers rates most inventive pharma in annual studyEli Lilly retakes innovation crown, while Bristol Myers rates most inventive pharma in annual study
fiercepharma.com - April 22 at 1:51 PM
Der 10. jährliche pharmazeutische Innovationsindex von IDEA Pharma: Eli Lilly ist zum ersten Mal das innovativste UnternehmenDer 10. jährliche pharmazeutische Innovationsindex von IDEA Pharma: Eli Lilly ist zum ersten Mal das innovativste Unternehmen
prnewswire.com - April 22 at 8:57 AM
Forbion closes final European life sciences funding round at €360M with help from Eli LillyForbion closes final European life sciences funding round at €360M with help from Eli Lilly
fiercebiotech.com - April 21 at 9:30 AM
Europe lung cancer therapeutics market is expected…Europe lung cancer therapeutics market is expected…
pharmiweb.com - April 20 at 1:03 PM
Eli Lilly, Incyte: Baricitinib Improves Hair Regrowth in Alopecia AreataEli Lilly, Incyte: Baricitinib Improves Hair Regrowth in Alopecia Areata
morningstar.com - April 20 at 1:03 PM
Why the Technicals for Eli Lilly $LLY can be More Revealing than the FundamentalsWhy the Technicals for Eli Lilly $LLY can be More Revealing than the Fundamentals
marketwatch.com - April 20 at 1:03 PM
Why Jim Cramer Is Closely Watching Eli LillyWhy Jim Cramer Is Closely Watching Eli Lilly
msn.com - April 20 at 1:03 PM
Why Organizations Must Reinvent Their Talent Strategy And Embrace Open InnovationWhy Organizations Must Reinvent Their Talent Strategy And Embrace Open Innovation
forbes.com - April 20 at 8:03 AM
Eli Lilly Says 2nd Late-stage Study Of Baricitinib Achieved Main Goal- Quick FactsEli Lilly Says 2nd Late-stage Study Of Baricitinib Achieved Main Goal- Quick Facts
markets.businessinsider.com - April 20 at 8:03 AM
Lilly and Incytes Baricitinib Improved Hair Regrowth for Alopecia Areata Patients in Second Phase 3 StudyLilly and Incyte's Baricitinib Improved Hair Regrowth for Alopecia Areata Patients in Second Phase 3 Study
finance.yahoo.com - April 20 at 8:03 AM
FDA limits emergency use of Eli Lilly COVID-19 antibody drugFDA limits emergency use of Eli Lilly COVID-19 antibody drug
beckershospitalreview.com - April 19 at 4:57 PM
As variants take hold, FDA revokes authorization of Eli Lillys solo COVID-19 antibodyAs variants take hold, FDA revokes authorization of Eli Lilly's solo COVID-19 antibody
fiercepharma.com - April 19 at 4:57 PM
Postoperative Management Market to account to USD…Postoperative Management Market to account to USD…
pharmiweb.com - April 19 at 11:56 AM
Lilly (LLY) to End Solo Bamlanivimab Use, Back COVID-19 ComboLilly (LLY) to End Solo Bamlanivimab Use, Back COVID-19 Combo
finance.yahoo.com - April 19 at 11:56 AM
Eli Lilly And Incyte’s Baricitinib Fails To Meet Endpoint In Phase 3 COVID-19 TrialEli Lilly And Incyte’s Baricitinib Fails To Meet Endpoint In Phase 3 COVID-19 Trial
finance.yahoo.com - April 19 at 11:56 AM
US revokes authorisation of one of Eli Lillys cocktailUS revokes authorisation of one of Eli Lilly's cocktail
bignewsnetwork.com - April 18 at 1:11 AM
Lilly Seeks to Revoke Emergency Use Authorization for COVID-fighting AntibodyLilly Seeks to Revoke Emergency Use Authorization for COVID-fighting Antibody
insideindianabusiness.com - April 16 at 6:33 PM
The Latest: Decreasing demand for vaccines in KansasThe Latest: Decreasing demand for vaccines in Kansas
marketbeat.com - April 16 at 5:08 PM
The Latest: Infections in Turkey soar to record levelsThe Latest: Infections in Turkey soar to record levels
marketbeat.com - April 16 at 1:55 PM
Eli Lilly: Antibody combo works best on COVID-19 variantsEli Lilly: Antibody combo works best on COVID-19 variants
ibj.com - April 16 at 1:33 PM
Eli Lillys Olympic athletes share health challenge stories in the countdown to GamesEli Lilly's Olympic athletes share health challenge stories in the countdown to Games
fiercepharma.com - April 16 at 1:33 PM
Eli Lilly asks FDA to revoke approval for use of antibody drug by itselfEli Lilly asks FDA to revoke approval for use of antibody drug by itself
upi.com - April 16 at 1:33 PM
The Latest: WH: $4B to American Indian tribes for virusThe Latest: WH: $4B to American Indian tribes for virus
marketbeat.com - April 16 at 1:08 PM
The Latest: US sets up $1.7B network to track virus variantsThe Latest: US sets up $1.7B network to track virus variants
marketbeat.com - April 16 at 12:38 PM
The Latest: Eli Lilly: Antibody combo works best on variantsThe Latest: Eli Lilly: Antibody combo works best on variants
marketbeat.com - April 16 at 10:36 AM
Lilly asks FDA to not allow lone use of COVID-19 drug bamlanivimabLilly asks FDA to not allow lone use of COVID-19 drug bamlanivimab
news.trust.org - April 16 at 8:33 AM
Lilly asks FDA to revoke authorization for lone use of COVID-19 drug bamlanivimabLilly asks FDA to revoke authorization for lone use of COVID-19 drug bamlanivimab
reuters.com - April 16 at 8:33 AM
New Covid-19 Strains Prompt Lilly to Seek to End U.S. Use of Single Antibody Drug AloneNew Covid-19 Strains Prompt Lilly to Seek to End U.S. Use of Single Antibody Drug Alone
wsj.com - April 16 at 8:33 AM
BRIEF-Lilly Requests Revocation Of Emergency Use Authorization For Bamlanivimab Alone To Complete Transition To Bamlanivimab And Etesevimab Together For Treatment Of Covid-19 ...BRIEF-Lilly Requests Revocation Of Emergency Use Authorization For Bamlanivimab Alone To Complete Transition To Bamlanivimab And Etesevimab Together For Treatment Of Covid-19 ...
msn.com - April 16 at 8:33 AM
3 Recession-Proof Dividend Stocks to Buy Now (LLY)3 Recession-Proof Dividend Stocks to Buy Now (LLY)
marketbeat.com - February 1 at 5:14 PM
Follow Eli Lillys (NYSE:LLY) Lead, and Make a  Big PurchaseFollow Eli Lilly's (NYSE:LLY) Lead, and Make a Big Purchase
marketbeat.com - December 15 at 11:42 AM
How to Invest After a Turbulent 2020 Election (LLY)How to Invest After a Turbulent 2020 Election (LLY)
marketbeat.com - November 23 at 5:51 PM
Amgen (NASDAQ:AMGN) Proves the Value of Diversification (LLY)Amgen (NASDAQ:AMGN) Proves the Value of Diversification (LLY)
marketbeat.com - October 29 at 11:54 AM
DateCompanyBrokerageAction
3/22/2021Eli Lilly andTruist SecuritiesBoost Price Target
2/12/2021Eli Lilly andCowenBoost Price Target
2/4/2021Eli Lilly andMorgan StanleyBoost Price Target
2/1/2021Eli Lilly andMizuhoBoost Price Target
2/1/2021Eli Lilly andBarclaysBoost Price Target
1/22/2021Eli Lilly andBank of AmericaBoost Price Target
12/10/2020Eli Lilly andWolfe ResearchUpgrade
11/10/2020Eli Lilly andSanford C. BernsteinInitiated Coverage
10/16/2020Eli Lilly andJPMorgan Chase & Co.Boost Price Target
9/29/2020Eli Lilly andBerenberg BankInitiated Coverage
6/16/2020Eli Lilly andGuggenheimUpgrade
(Data available from 4/22/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.